Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 10/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.34 |
| ▸ | USP2 | O75604 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381152 | 0.80 | EPHX2 (0.38) | CYP3A4EPHX2ALDH1A1 | |
| SCHEMBL25701698 | 0.76 | CYP2D6 (0.51) | CYP2D6SMN1; SMN2HRH3CYP2C19CYP3A4 | |
| SCHEMBL25701697 | 0.75 | CYP2D6 (0.49) | CYP2D6SMN1; SMN2HRH3CYP2C19CYP3A4 | |
| SCHEMBL26144775 | 0.74 | HRH3 (0.37) | CYP2D6SMN1; SMN2HRH3CYP2C19CYP3A4 | |
| SCHEMBL12599351 | 0.74 | HRH3 (0.37) | CYP2D6SMN1; SMN2HRH3CYP2C19CYP3A4 | |
| SCHEMBL25702903 | 0.74 | CYP2D6 (0.48) | CYP2D6SMN1; SMN2HRH3CYP2C19CYP3A4 | |
| SCHEMBL25707865 | 0.74 | CYP2D6 (0.49) | CYP2D6SMN1; SMN2HRH3CYP2C19CYP3A4 | |
| SCHEMBL13100462 | 0.72 | — | — | |
| SCHEMBL16259693 | 0.72 | HRH3 (0.45) | CYP2D6SMN1; SMN2HRH3CYP2C19CYP3A4 | |
| SCHEMBL25708207 | 0.71 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2HRH3CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-02 | — | — | US | claimed |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | claimed |
| US-10590083-B2 | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-17 | — | — | US | disclosed |
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-03 | — | — | US | disclosed |
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-02 | — | — | US | disclosed |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047959-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | CYP2D6 258/4885SMN1; SMN2 3697/4885HRH3 1300/4885 |
| US-10590083-B2 | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | CYP2D6 284/4885SMN1; SMN2 3686/4885HRH3 1350/4885 |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | CYP2D6 258/4885SMN1; SMN2 3697/4885HRH3 1300/4885 |
| US-20190047959-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | CYP2D6 284/4885SMN1; SMN2 3686/4885HRH3 1350/4885 |
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | CYP2D6 266/4885SMN1; SMN2 3825/4885HRH3 1285/4885 |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | CYP2D6 266/4885SMN1; SMN2 3825/4885HRH3 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.